**FOI Ref: 6192**

**Category(ies): Clinical - Drugs**

**Subject: Dermatology Biologic Drugs**

**Date Received: 19/01/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:* Adalimumab - Humira
* Adalimumab Biosimilar
* Apremilast
* Bimekizumab
* Brodalumab
* Certolizumab
* Dimethyl fumarate
* Etanercept - Enbrel
* Etanercept Biosimilar
* Guselkumab
* Infliximab - Remicade
* Infliximab Biosimilar
* Ixekizumab
* Risankizumab
* Secukinumab
* Tildrakizumab
* Ustekinumab
 |

|  |  |
| --- | --- |
| Name of Biologic Drug | Number of patients treated in last 3 months |
| Adalimumab - Humira |  N/A |
| Adalimumab Biosimilar | 101 |
| Apremilast  | 0 |
| Bimekizumab | 0 |
| Brodalumab | 6 |
| Certolizumab  | 9 |
| Dimethyl fumarate  | 0 |
| Etanercept - Enbrel | 0 |
| Etanercept Biosimilar | 0 |
| Guselkumab  | 105 |
| Infliximab - Remicade | 0 |
| Infliximab Biosimilar | 0 |
| Ixekizumab  | 16 |
| Risankizumab | 21 |
| Secukinumab  | 86 |
| Tildrakizumab | 0 |
| Ustekinumab | 115 |

 |